Skip to main content
Clinical Trials/CTRI/2018/05/013548
CTRI/2018/05/013548Active, not recruiting未知

Evaluation of the effect of omega-3 fatty acid alone and in combination with Proprietary Chromium Complex (PCC) 200mcg and 400mcg on endothelial dysfunction in metabolic syndrome

izams Institute of Medical Sciences0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1.Male and female subjects between 30-65 years and willing to give informed consent and comply with protocol related study procedures.
  • 2.Subjects having endothelial dysfunction defined as ââ?°Â¤ 6% change in reflection index (RI) on post salbutamol challenge test.
  • 3. Subjects who comply with ââ?¬Å?The International Diabetes Federationââ?¬? guidelines dated 2006
  • 4. Subjects not on any investigational products in the past 6 months.

Exclusion Criteria

  • 1.Subjects with abnormal hematological or biochemical parameters considered significant by investigator.
  • 2.Uncontrolled hypertension ( SBP >180mmHg and DBP >100mmHg).
  • 3.Serum Triglycerides >500mg/dl.
  • 4.AST and ALT elevation >3 times upper limit of normal.
  • 5.Serum creatinine more than 1.5 mg/dl.
  • 6.On any other dietary or herbal supplements.
  • 7.History of malignancy or stroke.
  • 8.Smoking, chronic alcoholism.
  • 9.Any medical condition where physician feels participation in the study could be detrimental to subjects well being.

Investigators

Sponsor
izams Institute of Medical Sciences

Similar Trials